Trials / Conditions / Unresectable Head and Neck Squamous Cell Carcinoma

Unresectable Head and Neck Squamous Cell Carcinoma

11 registered clinical trials studyying Unresectable Head and Neck Squamous Cell Carcinoma — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squ NCT07156227	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinom NCT06790966	PDS Biotechnology Corp.	Phase 3
Active Not Recruiting	Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Tr NCT04576091	National Cancer Institute (NCI)	Phase 1
Recruiting	Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli NCT05269381	Mayo Clinic	Phase 1 / Phase 2
Withdrawn	Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recu NCT04834349	M.D. Anderson Cancer Center	Phase 2
Recruiting	A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With NCT04534205	BioNTech SE	Phase 2 / Phase 3
Completed	Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer NCT04870840	M.D. Anderson Cancer Center	Phase 1
Terminated	Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat NCT03823131	Chase Heaton, MD	Phase 2
Active Not Recruiting	Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer NCT03468218	Emory University	Phase 2
Completed	Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malig NCT03229278	Rutgers, The State University of New Jersey	Phase 1
Active Not Recruiting	Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Nec NCT01468896	National Cancer Institute (NCI)	Phase 1 / Phase 2